|
Announcing BioTrinity 2008 - Oxford
April 15-16, Quadrangle at Kassam, Oxford, UK
Biopartnering and showcasing UK's most successful biotech super-cluster
Partner with the best of hundreds of companies in the Oxford & South East BioCluster. Companies in the Oxford BioCluster alone having completed financings worth over £313m since 2005*, with the total value of M&A deals being £530m, a total of over 1.13bn Euro.
BioTrinity 2008 - Oxford brings together key players and decision makers from the biotech industry, featuring a gold-standard one-to-one partnering service with private partnering rooms as standard, company showcase presentations of both the most promising emerging companies and companies with compounds in clinical trials, panel discussions and a high visibility exhibition.
Positioned as the Oxford & South-East BioCluster's equivalent of the ERBI Bioexchange and London's Genesis conferences, BioTrinity 2008 - Oxford is competitively priced to provide the leading summit and networking venue for SME biotechs to meet pharma, investors, innovators, scouts and tech transfer agents.
BioTrinity is productive: catering for over 500 partnering meetings, over 400 delegates from nearly 300 companies, with over 180 licensing opportunities in its inaugural year, and this year we've increased our capacity.
Read the glowing testimonials from last year
BioTrinity 2008 speakers include:
- Atlas Venture (Life Sciences Principal)
- Shire Pharma (VP Licensing)
- Merck (Director Scientific Liaison)
- Evotec UK Limited (EVP, Business Development)
- (OSI) Prosidion, President
- Summit plc (CEO)
- Glide Pharma (CEO)
- Chemocentryx (CEO)
- Celleron Therapeutics (CEO)
- Genzyme (VP and GM)
- Hybrid Systems(CEO)
- Oxford Capital Partners (Co-founder and Investment Director)
- Solace Pharma (CEO)
Among our recent BioTrinity delegates see which companies have already signed up.
*Source: OBN BioCluster Report 2008 (to be published at BioTrinity).
...........................................................................................
BioTrinity 2008 testimonials:
Testimonial from a Venture Capitalst firm (read more testimonials):
"...the conference was a great success. There was a high calibre of participants and the event has raised the profile the Oxford and Thames Valley biotech cluster. This will create a rising tide for us all."
David Mott, Investment Director, Oxford Capital Partners
...........................................................................................
BioTrinity 2008 features:
-
Two full days of partnering in private rooms as standard for under £500!
-
A multi-track programme incorporating Key-notes and Key-deals by prominent speakers on the growth and development of the sector; Panel discussions on Venture Capital; Alliances and Licensing; The Most Promising Emerging Companies showcase; Clinical Stage Developments showcase; Technology showcase of licensing opportunities and spin outs; Sponsor led and independent workshops on deal making, funding, business planning and alliance; the Bio-IT Showcase
- Two networking events (including the launch of the OBN 2008 BioCluster Report) and ample opportunities for informal networking via breakfasts, lunches and refreshment breaks.
A high visibility exhibition amidst partnering terminals, catering and networking areas. In par with BioTrinity 2007, spaces are selling fast.
............................................................................................
Contact details:
Aruna Dudhia – Events Manager OBN
Suite L, Park House
11 Milton Park, Abingdon
Oxfordshire OX14 4RA
Tel. +44 (0) 1865 594641
Fax. +44 (0) 1235 835843
aruna.dudhia@oxfordshirebioscience.net
Register online now at www.biotrinity.com
............................................................................................
BioTrinity sponsors
  
  
   
............................................................................................
BioTrinity partners
 
 
|
BioTrinity 2008
-
-
-
-
-
-
-
-
Plenary, Key Deals and Developments
-
Panel Discussions (Venture Capital, Alliances and Licensing)
-
Company Showcase featuring Emerging Companies and Clinical Stage Developments
-
Technology Showcase (includes opportunities from Isis Innovation)
-
Bio-IT Showcase
-
-
-
Formal and Informal Networking
-
|
)